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Portal-systemic shunting of blood is associated with hyperammonemia, an increased glutamine concen-
tration in brain, an altered plasma neutral amino acid pattern, and high levels of several of the large
neutral amino acids in brain. Since some of these amino acids are precursors for neurotransmitters and
for other potentially neuroactive substances, high CNS levels of these amino acids may contribute to the
development of encephalopathy. In order to determine the relative importance of changes in brain
glutamine levels and changes in competition among the neutral amino acids for blood-brain transport,
we measured the concentrations of the large neutral amino acids in plasma, cisternal cerebrospinal fluid
and in brain tissue from various regions of dogs after end-to-side portacaval shunt. Although the
changes in CSF amino acid levels correlated partially with altered amino acid plasma competitor ratios,
better correlations were observed with the elevation of CSF glutamine. These results suggest a model of
blood-brain amino acid transport in which a high level of glutamine in brain extracellular fluid competes
with other neutral amino acids for efflux from brain, thus raising brain amino acid levels after portal-
systemic shunting.
KEY WORDS: Portacaval anastomosis, portal-systemic, encephalopathy, brain and CSF glutamine,
large neutral amino acids, blood-brain barrier
INTRODUCTION
One of the interesting problems in the study of hyperammonemia, liver failure and
portal-systemic encephalopathy is the relationship of changes in the brain of the
neurotransmitter-precursor amino acids to the development of encephalopathy.
The amino acids of particular interest are tyrosine, phenylalanine and tryptophan,
since they are involved in the synthesis in the brain of catecholamines, serotonin
and of potential false transmitters such as octopamine or tryptamine7’5. These
amino acids, together with leucine, isoleucine, valine, methionine, threonine and
histidine, comprise the group of large neutral amino acids (LNAA) which share a
common blood-brain transport system. In both humans and experimental animals
with hepatic failure, many LNAA accumulate in the CNS to a greater extent than
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the changes in plasma concentrations of those amino acids would seem to
predict18’11’15. The reason for this "excess" accumulation of LNAA in the CNS of
patients or experimental animals with portal-systemic shunting and hyperammone-
mia has not been completely explained, although data have been presented which
point to a role for elevated glutamine concentrations in the CNS in altering LNAA
transport at the blood-brain barrier1’12’13. In the following study in dogs, we
compared the changes after portacaval anastomosis (PCA) in LNAA concentra-
tions in plasma, cisternal CSF and in brain tissue. The latter was obtained only at
sacrifice, but the plasma and CSF were sampled sequentially after PCA in order to
follow changes over time. The results point to a significant role of elevated brain
GLN as a competitor for efflux of the LNAA from the brain to the blood.
MATERIAL AND METHODS
Sixteen conditioned dogs weighing 9.5-23.9 kg were studied. Twelve dogs were
anesthetized with sodium pentobarbital and subiected to an end-to-side portacaval
shunt. The anastomosis was done with 5-0 Prolene sutures using the portal vein
stump above the last splanchnic branch. After the operation 5% dextrose and
saline solution were infused for 24 hours and penicillin and streptomycin were
given. All dogs were allowed chow ad libitium. Weight, but not food intake, was
monitored. The remaining four unoperated dogs served as controls.
From previous experience in this laboratory
24 with this experimental model, we
anticipated that the development of encephalopathy in each dog would be difficult
to predict. We intended to sacrifice similar numbers of dogs in Stage I (mild), Stage
II (moderate) and Stage III (severe) encephalopathy. Therefore, starting from the
second postoperative day two observers independently rated the dogs for encepha-
lopathy. The parameters used for this evaluation were spontaneous activity, ataxia,
salivation, ease of arousal, response to foot pinching and abnormalities of gait. The
animals were clinically graded as follows:
Grade O: Indistinguishable from normal (no animals were sacrificed in this
condition).
Grade I: Less lively, with delayed responses.
Grade II: Hypersalivation; hyperactive movements; walking close to the walls
with an unsteady gait.
Grade III: Excessive salivation; sleeping most of the time; when forced to walk,
walking "into" walls; standing with great difficulty; very slow response
to foot-pinch; coma.
Samples were obtained as follows: Venous blood and CSF from the cisterna
magna were obtained from dogs, anesthetized with pentobarbital, preoperatively
and at 3-week intervals thereafter. Heparinaized blood was immediately cooled on
ice and centrifuged, and plasma was either processed immediately or kept frozen at
-70C. The plasma amino acid concentrations were determined by using a
Beckman 121 MB amino acid analyzer with automatic integration. The plasma was
deproteinized by mixing 0.5 ml plasma with 1.5 ml of 5% sulfosalicylic acid (pH
1.8, adjusted with LiOH) containing as an internal standard 133 nmol/ml thienyla-
lanine. CSF samples were prepared by mixing 0.9 ml CSF with 0.1 ml 37.5%BRAIN AND AMINO ACIDS 301
sulfosalicylic acid, pH 2.0, containing 500 nmol/ml thienylalanine. After that, all
samples were centrifuged (20,000 g, 20 min, 4C) and passed through a 0.4 um
filter (Millipore Corp.) and frozen at -70C until analysis.
At the time of sacrifice, the dogs were anesthetized with pentobarbital and blood
and CSF samples were taken. The vault of the skull was removed by an electric saw
and the brain disconnected at the junction with the spinal cord and rapidly
transferred to ice-cold normal saline. The brain was then put on its dorsal surface
on an ice-cold, saline-soaked paper towel. Nine regions of the brain were isolated
separately and in the following order: hypothalamus, diencephalon, cerebellum,
medulla, pons, mesencephalon, cortex, caudate nucleus, and hippocampus. The
brain samples were immediately frozen in liquid nitrogen and stored at -70C until
the analysis. On the average, the samples were frozen within 5 min after the brain
was removed. Hypothalamus was dissected by making a cut at a depth of
approximately 5 mm from just anterior to the optic chiasma to the posterior aspect
of the mamillary body bounded laterally by the choroid fissure. A sample was next
taken from the diencephalon just dorsal to the hypothalamus. Cerebellum was then
removed and a portion (1-2 g) taken for analysis. Pons was separated from the
medulla at the pontine fissure. Mesencephalon was removed from the rest of the
brain stem by a vertical cut just anterior to the superior colliculus. Next, the brain
was divided into the two hemispheres and both caudate nuclei were removed from
the lateral walls of the lateral ventricles. Hippocampal tissue was removed from the
temporal recessus of the lateral walls of the lateral ventricles and cortical samples
were taken from the temporoparietal areas.
The brain samples were homogenized in three volumes of 5% sulfosalicylic acid,
pH 1.4, containing 133 nmol/ml of thienylalanine as internal standard. The samples
were then handled in the same way as for plasma and CSF with the exception that
each sample was analyzed twice, i.e., once at the 1:4 dilution of the homogenate for
the low concentration amino acids, and then after further 1:25 dilution to measure
the high concentration amino acids glutamate and glutamine. Plasma, brain and
CSF were analyzed for threonine: (THR), glutamine (GLN), valine (VAL),
methionine (MET), isoleucine (ILE), leucine (LEU), tyrosine (TYR), phenylala-
nine (PHE), tryptophan (TRP), histidine (HIS), and (in brain only) alanine (ALA)
and glutamate (GLU).
Since one aim of this study is to determine whether the rise in the concentrations
of various LNAA in the CNS could be accounted for solely by changes in
circulating LNAA levels, the manner in which the circulating amino acid levels
should be expressed is of importance. Studies in rats have demonstrated that the
LNAA (THR, VAL, MET, ILE, LEU, TYR, PHE, HIS, TRP) compete for a
common blood-brain transport system 17’25. Glutamine can apparently be trans-
ported by this system also, but has a very low affinity for it 17’19. Each LNAA has a
characteristic affinity for the transport system, with some amino acids (e.g., LEU,
PHE) competing more effectively for transport than others (e.g., VAL, THR).
Studies from this laboratory in dogs have clearly demonstrated the effects of
competition among plasma amino acids on CSF levels of LNAA 24. Studies in dogs
by others have suggested that the rank-order of transport Km’s (affinities) is similar
to that in rats 25; however, no blood-brain transport Km values are available for
normal dogs or in dogs after PCS. We expressed the availability of a particular
amino acid for blood-brain transport in a form of the Michaelis-Menten kinetic
formula, which accounted for the competition among plasma amino acids due both302 T. JONUNG ET AL.
to their different concentrations in plasma and also to their presumed relative
affinities (Km). The plasma competitor ratios (PCR) of the studied amino acids
were calculated in a way similar to the brain influx rate used by Fernstrom and
Faller with the modification that the Vmax of transport was considered to be
100% as previously described 8. One interpretation of uptake expressed in this
fashion is that the calculated values represent the fraction of maximum transport
activity expended on a particular amino acid. It is assumed, in making these
calculations, that blood-brain LNAA transport does not greatly differ in dogs and
rats and that PCA does not alter the affinities (K), of the amino acids for the
transport system. The PCR were calculated as follows:
AAx
PCRx 100%
Kmx[1 + AA/Km] +AAx
where AAx is the plasma concentration of the NAAx; Kmx is the transport Km of
AAx; Km is the transport Km of competing NAA; AA is the plasma concentra-
tions of competing NAA; and Vmax is the transport Vmax 100%. The Km’s of
transport for each neutral amino acid from Pardridge and Mietus
19 and Pardridge
and Oldendorf
20 were as follows" THR 730 nmol/ml; VAL 510 nmol/ml; ILE
250 nmol/ml; LEU 100 nmol/ml; MET 180 nmol/ml; TYR 150 nmol/ml;
PHE 110 nmol/ml; and HIS 240 nmol/ml. Tryptophan concentrations were
not included in the calculation since the actual amount of "free’ or non-albumin-
bound tryptophan was not determined. This fraction of the plasma tryptophan is
relatively small and therefore exerts only slight competitive effect.
Statistical analysis of differences among serial samples of plasma and CSF was by
analysis of variance and Newman-Keuls test. Correlation was tested by Pearson
product-moment correlation. Comparison of amino acid concentrations in brain
regions of control dogs and dogs killed in various stages of encephalopathy is by the
non-parametric Kruskal-Wallis test.
RESULTS
The interval from PCA until development of encephalopathy and sacrifice was
highly variable, ranging from 21 to 213 days. The mean overall weight loss at time
of sacrifice was 26 + 3%. The percentage weight loss was proportional to the grade
of encephalopathy at time of sacrifice: 20 + 4% in grade I, 29 _+ 4% in grade II, and
34 +4% in grade III. At time of sacrifice six dogs were rated in grade I, 3 dogs in
grade II, and 3 dogs in grade III. It should be noted that, due to the unpredictability
of the course of encephalopathy after PCA in dogs, it proved difficult to achieve the
goal of equal numbers of dogs in each stage of encephalopathy. In practice, those
dogs which deteriorated quickly to stage II and III were sacrificed first, whereas
those dogs which showed little tendency to develop severe encephalopathy were
sacrificed at later times (up to several months) after surgery and were mostly in
stage I.
Table 1 compares the changes in LNAA concentrations or competitor ratios at
intervals after PCA with observed LNAA concentrations in cisternal CSF. The
changes in the plasma amino acid pattern after PCA were similar to thoseBRAIN AND AMINO ACIDS 303
previously reported
4 and characterized by increased concentrations of histidine
and of the aromatic amino acids tyrosine and phenylalanine. The calculated plasma
competitor ratios (Table 1) also changed after PCA in directions similar to the
absolute plasma amino acid concentrations. Note that preoperatively the percent-
age of calculated transport activity was greatest for LEU and PHE, reflecting their
high affinities for transport (low Km). After PCA the calculated ratios for PHE and
TYR approximately doubled, representing the greatest increase of any of the
LNAA in this parameter. The calculated competitor ratios for the BCAA dec-
reased to a greater extent than their absolute concentrations in plasma.
Table 1 Changes in plasma amino acid concentrations, calculated plasma competitor ratios, and
cisternal CSF concentrations at various times after PCA.
Plasma Plasma Competitor Ratio CSF
(nmol/ml +- SEM) (% Vmax +- SEM) fnmol/ml +- 5EM)
THR 203-+,?9 16 716 187.t21 162-+25
(-18%) (-8%) (-20%)
VAL 14J-+l 114-+J4 II 316 11716
(-20%)
ILE 37J 375
(0)
LEU 91’_15 82+]0
(-10%)
MET 45-+3 48+_4
(,7%)
TYR 32_+4 75+-7
PHE 43_+4
Hl 64-+3
TAP 59+_4
pre-op wk wk wk pre-op wk wk wk
NC -
148-13 20_64 Igl-r58
(+232%)a (+355%)a (+329%)a
6.3+0.7 5.0_+0.4 5.4+_0.6 5.0+-0.9
(-21%) (-14%) (-21%)
7.s-+0.2 4.8_0.3 4.6-+0.3 4.g_*o.s
(-21%) (-18%) (-36%) (-39%) (-35%)
34.-+5 37.-+ 3.4...D.2 3.0D.3 2.3+-0.2 2./+-0.4
(-8%) (O) (-12%) (-33%) (-21%)
/8*_Jl 790 22.7+-D.9 17.91.2 15.7D.9 17.1-+1.7
(+31) (-7) (-16%) (,3%) (-16%)
980 82 5.7.4 10.8.4 12.1.3 11.30.8
(+134%) (+206%)a(+156%) (+89%) (+112%) (+98%)
10210 13220 lO9+lO 10.3-+0.5 20.1_D.7 21.2_’1.5 20.6+_.I.9
(+137%) (+207%)a(+153%) (+95%) (106%) (+100%)
93-+7 lll-+ll 996 7.4-+0.4 8.6+_0.4 9.7+___0.4 9.00.9
(45%) (+83%) (+55%) (*16%) (+31%) (+22%)
669 8310 60-+9
(+12%) (41%) (+2%)
49 424_.5 4?. 44-+
(-14%) (-4%) (-10%)
ll-+J 12-+1 14J 16’_2
(*9%) +27%)a (45%)
4+-1 4.1 51 5]
(O) (+25%) (+25%)
13-+.] 14+-1 17+-1 19.3
(+8%) (+31%) (+46%)
18 23
(+125%) (*187%) (+162%)
g 32 s3 41/
(+256%) (*489) (+367%)
12+1 43-+3 72-+.8 6|+_14
(+258%) (+500%) (40)
131 3 49+-3 44"!0
(+162%) (+277%) (+238%)
5+-I 14"1 ]8-+2 17I
(+180%) (+260%) (+240%)
Percent change from pre-op indicated beneath values.
NC not calculated (see text).
Number of dogs pre-oPo 12; wk, I2; wk, 9; wk, 5.
Significantly different from controls; p<O.Oi
The CSF concentration of GLN, presumably the product of cerebral ammonia
detoxification with glutamic acid, rose after PCA to a much greater degree than in
plasma. The increases in the concentration of PHE, TYR, HIS and TRP in CSF
greatly exceeded the change either in absolute plasma levels or in the calculated
competitor ratios. In all brain regions of dogs with PCA, the concentrations of
GLN, TYR, PHE, TRP and HIS were several-fold higher than control, while MET
and LEU were increased to a lesser extent. The regional concentrations of alanine
(ALA) and of glutamic acid (GLU), the precursor for GLN synthesis, are also
shown in Table 2 for comparison, although they are not substrates for the LNAA
transport system of the blood-brain barrier. There was no consistent statistical
difference in regional amino acid levels between dogs sacrificed in encephalopathy304 T. JONUNG ET AL.
grade I as compared with dogs in grades II and III combined. Combining the data
of dogs in grade II and III was necessary to achieve sufficient numbers for statistical
analysis.
Table 2 Regional concentrations of amino acids in the brain of dogs before and after portacaval
anastomosis.
Bra Grade of
Region Encephalopathy Asnt no Acid
’HR GLU GLN LA VAL NET ILI LEU TYR PIlE TRP HIS
Oiencephalon Controls (4) 262 9039 4670 371 98 42 25 57 42 35 18 160
(6) 154 8125 22320 38I 95 92 29 88 235 244 65 544
II Ill (6) 157 8654 18184 378 122 62 35 123 22I 308 71 410
Hypotha 1amos Control 214 4359 3498 262 72 29 15 51 37 35 23 61
144 4861 13571 279 70 65 15 49 158 166 49 206
II Ill 132 5089 16463 425 87 62 21 77 144 196 52 194
Hedu la Control 263 5809 3468 421 107 44 35 63 51 SO 22 133
16S 6048 17941 428 Ill 63 38 84 247 291 63 420
II II! 124 5667 18847 365 136 86 33 103 210 321 68 368
Pons Control 278 5952 2984 406 83 37 22 60 48 50 22 115
192 4786 11734 375 86 105 19 73 246 322 63 376
II Ill 14l 519l 19149ab 458 90 86 27 100 319 32l 68 199
Cortex Controls 281 10654 6174 590 126 61 33 86 55 52 20 108
145 9460 23506 605 231 89 34 lOO 260 295 76 410
II Ill 128 9541 32773 596 238 69 36 134 247 266 76 303
Caudate Control 356 ]lSlO 7031 48l 93 45 24 72 48 47 24 103
Nucleus 184 ]0729 23709 548 73 lO1 27 89 234 230 67 34g
II Ill 141 10937 21287 906 ll5 71 42 12l 206 280 73 294
Hippocampus Controls 362 8451 4492 733 98 52 24 71 SI 41 20 172
189 8273 16954 753 88 83 23 84 234 23I 67 544
II Ill 122 9115 16894 755 116 65 36 111 203 273 63 509
Hesencephalon Controls 291 6239 3478 498 153 41 22 63 48 45 21 140
178 6217 18516 420 115 99 32 85 248 268 63 429
lI Ill 128 6637 19125 474 130 72 35 lO/a 223 296 65 444
Cerebe um Cont rol 345 856l 6566 370 112 Sl 27 95 59 6l 27 120
187 8753 17748 415 113 112 20 90 237 293 67 288
II Ill 154 8706 23030 513 134 79 22 131 232 351 61 292
Results are given as the median since non-parametric test was used for the calculations.
astgntftcantly different from the controls; p<O.05 at least.
bStgnt ftcant di fference between encephalopathy grade vs. grade I; p<O.OS at least.
We tested whether the concentration of each of the LNAA in CSF was more
closely correlated to the plasma competitor ratio of that amino acid or to the CSF
concentration of GLU (Table 3). For these correlations, 45 data-pairs were
considered, significant correlations were observed between the CSF concentrations
of THR, TYR, PHE and HIS and their respective plasma competitor ratios.
Significant correlations were also found between the CSF concentration of GLN
and that of MET, LEU, TYR, PHE and HIS. For all CSF amino acids except
THR, the correlation with CSF GLN was better (higher value of the correlation
coefficient (r) than with the plasma competitor ratio, suggesting that CSF LNAA
concentrations are more strongly influenced by the CNS concentration of GLN
than by the availability of LNAA for transport from the circulation. The relation-
ship between CSF GLN and the four LNAA with the best correlations are shown
graphically in Figure 1.BRAIN AND AMINO ACIDS 305
Table 3 Pearson product-moment correlations between CSF concentrations of LNAA and either the
plasma competitor ratio (PCR) or CSF GLN.
Amino Aci cl versus PCR versus CSF GLN
THR
(r) (r)
VAL
MET
ILE
LEU
TYR
PHE
HIS
a p<O.Ol
b p<O.O01
0.433 a 0.033
O. 170 O. 340
-0.138 0.654b
O. 057 O. 144
0.035 0.527b
0.720b O.g50b
0.790b 0.914b
0.439 a O.gO4b
A similar comparisons of correlations was performed between the regional brain
concentration of each LNAA and either the plasma competitor ratio or either
concentration of GLN in that region (Table 4). For these correlations, all 16 dogs
were considered. As in the CSF, the best correlations were observed for MET,
PHE, TYR and HIS. For MET and HIS, the better correlations were clearly with
the brain GLN concentration; whereas, for PHE and TYR, their brain concentra-
tions correlated about equally well both with the plasma competitor ratio and the
brain GLN level.
The correlation between CSF GLN and regional GLN was tested in the twelve
dogs with a PCS. The controls were omitted in this case since including them would
have markedly improved all the correlations, statistically significant correlation was
obtained only for cortex (r 0.645, p<0.05. Figure 2) and for cerebellum (r
0.593, p< 0.05). This result may reflect the fact that cerebral cortex and cerebellum
constitute two of the largest brain regions in dogs and, hence, diffusion of amino
acids from these regions may have considerable influence on the composition of
CSF.
DISCUSSION
The lack of correlation in the present studies between encephalopathy grade and
brain levels of amino acids, which are known or thought to be involved in synthesis306 T. JONUNG ETAL.
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Figure 1 Relationship between the CSF concentrations ofGLN and CSF concentrations of HIS, MET,
PHE and TYR. The data points shown represent pre-operative samples, clustered at lower left of each
panel, and all subsequent CSF samples obtained on all dogs. Correlation coefficients are shown in Table
3.
of true or false neurotransmitters, would seem to weaken the hypothesis that
changes in brain amino acid levels are involved in encephalopathy. However, it
should be noted that the design of the experiment may have resulted in significant
bias if there was some difference in "sensitivity" to high brain LNAA levels in those
dogs which exhibited encephalopathy at early or late times after the PCA. We have
no evidence, however, that such differences in sensitivity exist.
Models of blood-brain amino acid transport consider the existence of at least
three compartments: (a) blood or plasma, (b) brain extracellular fluid and the CSF,
and (c) the intracellular fluid of brain cells22. Amino acids in a cerebral capillary
must be transported across the two plasma membranes of the capillary endothelial
cell in order to enter the extracellular fluid where they are then available to the
transport systems of the brain cells themselves. Similarly, to exit from brain, amino
acids must cross the brain cell membrane into the extracellular fluid and then must
cross the two capillary membranes in order to reach the circulation. The totalBRAIN AND AMINO ACIDS 307
Table 4 Correlation of regional brain concentrations of several LNAA with the plasma competitor
ratio and with the regional brain GLN concentration.
METHIONI fiE TYROSI NE
Region PCR vs Brain Brain GLN vs Brain Region PCR vs Brain Brain GLN vs Brain
Concentration Concentration Concentration Concentration
(r) (r) (r) (r)
Dien 0.042 0.SgO Dien O.gOl O.gSOc
Hypo 0.254 0.482 Hypo 0.803 0.g24
Med -0.168 0.618b Med 0.852 0.g27
Pons -0.147 0.369 Ports 0.767c 0.694c
Cortex 0.185 0.536 Cortex 0.929 0.855
CN 0.173 0.513a CN O.g04c O.gO2
Hippo -0.135 0.461 Hippo 0.899 g.g2g
Mesen 0.002 0.601 Mesen 0.886 0.g14c
Cereb 0.208 0.6/6b Cereb 0.85/c 0.g28c
PHE NYLALANI NE HI ST DI NE
Region PCR vs Brain Brain GLN vs Brain Region PCR vs Brain Brain GLN vs Brain
Concentration Concentration Concentration Concentration
(r) (r) (r) (r)
Dien 0.951 0.948 Dien 0.670b 0.861c
Hypo 0.889 0.%2 Hypo 0.467 0.891c
Med 0.943C o.g80 Med 0.567 0.g38c
Pons 0.903 0.673b Pons 0.703b 0.395
Cortex 0.954 0.842 Cortex 0.590 0.680b
CN 0.972 0.957 CN 0.534a 0.g24c
Hippo 0.961 0.964c Hippo 0.563 9.941 c
esen 0.945 0.946 Mesen 0.540 0.933
Cereb 0.924 0.960 Cereb 0.$40 0.953c
p<o.o
b p<O.Ol
p<O.O01
capillary surface area is very small compared to the sum of brain cell membranes. It
has been proposed that the limiting factor in blood-brain transport of amino acids
(as well as of other substances requiring carrier-mediated transport) is transport
across the capillary membranes2.
In the present studies, with the exception of THR, the magnitude of the increase
or decrease in absolute plasma LNAA levels was not the same as the changes in
concentration of amino acids in CSF or in brain. The magnitude of change in the
calculated plasma competitor ratios for each LNAA was also considerably less than
the change in CSF or brain LNAA after PCA. These observations strongly suggest
that some factor other than the change in plasma LNAA concentrations was
responsible for the rise in CSF and brain LNAA levels after PCA.
Elevated concentrations of GLN in lumbar CSF are commonly found in patients
with encephalopathy resulting from liver disease 9. The synthesis in brain of GLN
from ammonia and glutamic acid apparently occurs very rapidly and primarily in
glial astrocytes, where the enzyme glutamine synthetase is located16. The elevated
CSF GLN concentration in patients almost certainly reflects accelerated detoxifica-
tion of ammonia in brain secondary to hyperammonemia14. In the present studies,
the CSF GLN concentration rose from levels which were less than those in plasma
preoperatively to levels which were markedly greater than in plasma (Table 1).308 T. JONUNG ET AL.
3000
z 2000-
1000
10 15 20 25 30 35
CORTEX GLN (,umol/g)
Figure 2 The relationship of cisternal CSF GLN to GLN in cortex in the twelve dogs with PCA at time
of sacrifice (r 0.645, p< 0.05).
This change in the CSF/plasma GLN ratio is strong evidence that transport of GLN
from extracellular fluid to blood across the capillary barrier was slow compared to
the rate of GLN synthesis, at least until CSF GLN reached a much higher level.
Presumably, at the higher level, synthesis of GLN was matched by the rate of
removal of GLN from the ECF. The present studies suggest that competition for
transport from ECF to blood among GLN and the other LNAA can be an
important determinant of brain LNAA levels in liver disease.
The increased CSF concentration of several of the LNAA was better correlated
with the increased CSF GLN concentration than with the change in the plasma
competitor ratios of those amino acids (Table 3). This does not imply that
competition among plasma neutral amino acids for transport across the blood-brain
barrier is not an important determinant of brain amino acid levels. On the contrary,
Smith, et al.
24 showed that infusing a solution rich in the BCAA could drastically
reduce the CSF levels of the other LNAA in dogs with portal-systemic encephalo-
pathy. The lower degree of correlation between plasma competitor ratios and CSF
LNAA levels suggests that, under the pathological conditions of the present study,
the GLN concentration in the CNS was a more important determinant of the
concentrations of the LNAA in the brain or CSF.
The most direct means by which a high concentration of GLN in the brain ECF
might affect the levels of other LNAA in brain ECF is for GLN to compete with theBRAIN AND AMINO ACIDS 309
other LNAA for transport out of brain. If transport of the LNAA across the
capillary endothelial barrier in the blood-to-brain direction is, as is thought,
primarily determined by competition, then it is very likely that transport in the
brain-to-blood direction is primarily determined by competition also. Increased
concentrations of GLN in CSF would inhibit the efflux of other LNAA until
sufficient concentrations of the other LNAA had accumulated in the ECF to
overcome this competition for transport out of brain. At this new steady state the
relationship between influx and efflux of the LNAA would be restored to more
normal levels. Accordingly to this hypothesis, the rise in LNAA concentrations in
the ECF would be a necessary and passive consequence of the increase in GLN
concentration in the same compartment.
The rise in brain intracellular concentrations of the LNAA may be explained by
assuming that the amino acid transport systems of brain cells include concentrative
mechanisms which actively "pump" amino acids into brain cells against their
concentration gradients:3. If it is further assumed that these transport systems are
capable of establishing a gradient with a fixed inside/outside concentration ratio of
3:1 to 4:1, then the rise in brain LNAA concentrations would follow as a simple
consequence of the rise in ECF LNAA concentrations. In the present studies, the
observation that the changes in CSF and in brain tissue amino acids were of similar
magnitude after PCA is consistent with this assumption.
It should be recalled that the metabolic fate of the various LNAA will affect their
final concentrations intracellularly. None of the LNAA, except GLN and perhaps a
small amount of TYR (from pilE), can be synthesized in brain. The brain can
metabolize the leucine and probably the other BCAA 3. It is therefore likely that
the small change in brain levels of the BCAA after PCA, as compared with the
greater increase in the AAA, is due in part to more rapid metabolism of the
BCAA. It is nonetheless notable that brain and CSF LEU concentrations rose after
PCA even though plasma LEU fell.
This hypothetical sequence of events does not require that the rate of transport
of LNAA across the blood-brain barrier actually be increased in the presence of
hyperammonemia and portal-systemic shunting. Changes in the rate of such
transport have been observed in rats after PCA 11’26’15, but attempts to demonstrate
accelerated blood-brain transport in dogs after PCA have not been successful1. If
the unidirectional flux ofLNAA from blood to brain was, in fact, increased in dogs
with PCA, then the principal effect of this would be to accelerate the accomplish-
ment of the new steady state levels of LNAA inthe ECF, which in turn is
determined by the ECF GLN concentration.
These various factors affecting LNAA levels after PCA in CSF or in brain tissue
are summarized schematically in Figure 3. Compared to normal (A), the only
change shown immediately after PCA (B) is a rise in blood ammonia. In actuality
the changes in blood ammonia and in plasma LNAA concentrations probably
proceed simultaneously, but for the purpose of discussion we will consider these
two processes as distinct. As a consequence of hyperammonemia, the synthesis of
glutamine in astrocytes is stimulated, resulting in increased brain GLN concentra-
tions. Panel (B) also represents a hypothetical but possibly observable moment
when brain GLN is elevated, yet the CSF GLN level has not yet begun to rise.
According to the role of GLN in blood-brain LNAA transport proposed previously
in this discussion, no change in CSF or brain LNAA levels should occur before CSF
GLN becomes elevated.310 T. JONUNG ET AL.
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Figure 3 Proposed schema reflecting events which occur after PCA in blood, CSF or extracellular fluid
(ECF) and brain compartments with respect to ammonia (NH3), BCAA and AAA. Panel A shows
normal pre-operative levels of ammonia and amino acids in blood plasma, CSF and brain tissue. Smaller
type-face in ECF reflects much lower concentrations in that compartment. Panel B represents a
hypothetical period after creation of the PCA when blood ammonia is elevated, thus raising the brain
GLN concentration, but before the CSF concentrations of GLN has risen and thus before blood-brain
NAA transport has been affected.
In Panel C, plasma levels of AAA are elevated while those of BCAA are decreased, thus altering
plasma competitor ratios. High GLN in the ECF plus altered competition for transport result in greatly
increased brain AAA concentrations.
In panel (C) the characteristic changes in plasma LNAA after PCA alter the
plasma competitor ratios and thus the ratio of AAA/BCAA which can be trans-
ported into brain. The elevated ECF GLN now competes for brain-to-blood
transport with the other LNAA, resulting in higher ECF and thus brain levels of
the AAA. Brain levels of BCAA are little affected both because the influx of
BCAA is somewhat reduced and because these amino acids are metabolized in
brain.
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Footnote
In conducting this research, the investigators adhered to the "Guide for the Care
and Use of Laboratory Animals" as promulgated by the Committee of Care and
Use of Laboratory Animals in the Institute of Laboratory Animal Resources,
National Research Council.
(Accepted by S. Bengmark 23 April 1991)
INVITED COMMENTARY
The CNS findings in PSE animals are impressive and confirm previous studies
showing a relation between the amino acid changes and CNS ammonia metabolism
with CNS glutamine accumulation and abnormal neurotransmission2. However, a
major question remains untested.Are the changes demonstrated as a result of PSE
or liver failure? The decrease in the ratio of BCAA/AAA has already been shown
to occur in liver dysfunction in the absence of PSE3, to decrease further with the
development of cirrhosis4 and to associated increase with an improvement in liver
function on Prednisone therapy5. Furthermore, these changes may be only secon-
darily associated with liver dysfunction; closely associated with elevated insulin
levels and may in themselves affect hepatocyte protein synthesis and therefore
plasma amino acid levels7. Thus it appears clear that the correct control group for
the PCA animal model is an animal model of liver disease in the absence of PSE.
For example, chronic bile duct ligation.
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